Ignite Creation Date:
2024-05-06 @ 3:34 PM
Last Modification Date:
2024-10-26 @ 1:51 PM
Study NCT ID:
NCT04671290
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2020-12-01
Brief Title:
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae
Sponsor:
Centre Hospitalier Annecy Genevois
Organization:
Centre Hospitalier Annecy Genevois
Study Overview
Official Title:
Temocillin Versus Carbapenems for Urinary Tract Infection Due to ESBL-producing Enterobacteriaceae a Multicenter Case-control Study
Status:
COMPLETED
Status Verified Date:
2020-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TEMO-BLSE
Brief Summary:
To assess the efficacy of temocillin compared to carbapenems for the management of ESBL-E UTI
Detailed Description:
Adults with a definite diagnosis of ESBL-E UTI between January-2015 and October-2019 were enrolled in a multicenter retrospective case-control study Cases were treated with temocillin 50 of the effective antibiotic therapy duration Control exclusively received carbapenem over the effective antibiotic therapy duration
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None